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Abstract:  The diagnostics of respiratory viral infections has improved markedly during the last 15 years with the 
development of PCR techniques. Since 1997, several new respiratory viruses and their subgroups have been discovered: 
influenza A viruses H5N1 and H1N1, human metapneumovirus, coronaviruses SARS, NL63 and HKU1, human 
bocavirus, human rhinoviruses C and D and potential respiratory pathogens, the KI and WU polyomaviruses and the 
torque teno virus. The detection of previously known viruses has also improved. Currently, a viral cause of respiratory 
illness is almost exclusively identifiable in children, but in the elderly, the detection rates of a viral etiology are below 
40%, and this holds also true for exacerbations of chronic respiratory illnesses. The new viruses cause respiratory 
symptoms like the common cold, cough, bronchitis, bronchiolitis, exacerbations of asthma and chronic obstructive 
pulmonary disease and pneumonia. Acute respiratory failure may occur. These viruses are distributed throughout the 
globe and affect people of all ages. Data regarding these viruses and the elderly are scarce. This review introduces these 
new viruses and reviews their clinical significance, especially with regard to the elderly population. 
Keywords: Bocavirus, coronavirus, elderly, influenza virus, metapneumovirus, polyomavirus, respiratory infection, torque teno 
virus. 
INTRODUCTION 
  Life expectancy has increased globally over the past two 
centuries by almost 30 years [1] and only over the last five 
decades by almost 20 years. This very recent phenomenon 
emerged as a consequence of improvements in nutrition, 
hygiene, antimicrobial therapy and vaccinations [2, 3]. The 
development of antiviral therapy, has, however, lagged 
behind. In the elderly, respiratory viral infections still cause 
significant morbidity and mortality: up to 40% of non-
pneumonic lower respiratory illnesses have been linked to 
respiratory viral infection, and in USA alone, an estimated 
54,000 annual deaths have been attributed to the influenza 
and respiratory syncytial viruses (RSV) [4-11]. 
  A milestone in the diagnostics of respiratory viral 
infections was the discovery of influenza A virus in 1933 
[12]. After the discovery of the coronaviruses in 1965, no 
new respiratory viruses or significant virus strains were 
identified in 32 years. The development of polymerase chain 
reaction (PCR) techniques in the 1990s initiated a new wave 
in viral diagnostics. The first avian flu epidemic in humans 
caused by influenza virus H5N1 struck in 1997 and alerted 
healthcare professionals by its severity [13]. In the same 
year, a virus family never seen in humans before, was 
identified: the anellovirus, the torque teno virus (TTV) as a 
signature virus, was found, but their link to human illnesses  
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has not been clarified [14-16]. In 2001, human metapneumo-
virus (MPV) was found followed by the discoveries of other 
new and significant respiratory viruses and virus strains: the 
coronaviruses SARS, NL63 and HKU1, the human 
bocavirus (HBoV), new human rhinovirus (HRV) strains 
(HRV-C and HRV-D), influenza A virus H1N1, and, as 
potential respiratory pathogens, the polyomaviruses KI and 
WU [17-28]. This review introduces these new viruses and 
reviews their clinical significance, especially with regard to 
the elderly population. 
SEARCH STRATEGY AND SELECTION CRITERIA 
  We made systematical searches through the PubMed data 
base for articles published before March 5, 2011 and indexed 
with the following search terms: elderly; and influenza 
H5N1 virus; influenza H1N1 virus; metapneumovirus; 
coronavirus SARS, NL63, or HKU1; bocavirus; rhinovirus C 
or D; polyomavirus KI or WU; or torque teno virus. We 
reviewed only articles published in English. 
INFLUENZA VIRUSES H5N1 AND H1N1 
  The most severe epidemics have been caused by the 
influenza A virus. In 1918-1919 the H1N1 virus pandemic 
resulted in an estimated 50 to 100 million deaths [29]. The 
mortality was surprisingly high among young adults. The 
most recent pandemics have usually been caused by the 
influenza A virus strain H1N1 and H3N2. The 2009 H1N1 
virus was highly contagious from human to human [30, 31]. 
In USA, the prevalence of H1N1-associated deaths was 12 
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in persons aged ! 65 years [31]. Similarly, H5N1 which had 
its source in birds, has infected humans since 1997, and has, 
by March 2011, been associated with high mortality; of 528 
patients with confirmed disease, 311 (59%) have died [13, 
30,  32, 33]. The mortality rate associated with H5N1 
infection has been 89% among children aged <15 years [32]. 
Elderly are often protected by pre-existing antibodies from 
previous illnesses, maybe even decades back [28, 30, 31]. 
On the other hand, the risk of severe illness is markedly 
increased by underlying medical conditions, especially 
chronic obstructive and other pulmonary diseases, 
immunosuppression, diabetes, obesity, or chronic heart 
conditions, which often accompany old age. 
  Influenza viruses typically cause mid-winter epidemics. 
The typical respiratory symptoms (cough, fever and sore 
throat), however, are poorly associated (43%) with 
confirmed influenza illnesses in older adults [34, 35]. 
Hypoxia and chest radiographs consistent with the acute 
respiratory distress syndrome are characteristic of patients 
requiring intensive care [34]. If death occurs, it follows 
approximately more than one week after the onset of 
symptoms and mortality correlates with high virus titers. The 
cause of death is usually progressive cardiopulmonary 
failure. The influenza-related morbidity in the elderly is 
closely related to the prevalence of influenza virus infections 
among children (reservoir) [36]. The diagnosis is mainly 
based on antigen detection and PCR of respiratory specimen, 
but culture and serology are also available. Treatment 
options are neuraminidase inhibitors (oseltamivir and 
zanamivir) or adamantane derivatives (amantadine and 
rimantadine) [37]. Systemic corticosteroids are not effective 
and may, in fact, increase the risk of hospital-acquired 
pneumonia and superinfections [38]. Strain-specific 
influenza vaccination is usually available after 6 to 12 
months after emergence of pandemic and has usually high 
immunogenicity among elderly subjects [39]. 
HUMAN METAPNEUMOVIRUS 
  Human metapneumovirus (MPV) causes upper and lower 
respiratory infections in patients of all ages, but mostly in 
children aged less than 5 years [17]. In healthy elderly 
subjects, MPV-infection is rare: one large study showed 
MPV RNA in nasal specimens in 1-2% of symptomatic and 
in 0-2% of asymptomatic elderly subjects [40]. In another 
study, MPV was only found in 2% of patients with acute 
exacerbation of chronic obstructive pulmonary disease 
(COPD) [41]. The prevalence of symptomatic MPV 
infection is higher (up to 4-7%) in residents of long-term 
care facilities [40]. During outbreaks, up to 72% of elderly 
institutionalized persons may fall ill, 31% may develop 
radiographically confirmed pneumonia and 50% may die 
[42, 43]. 
  In adults and elderly, MPV typically causes influenza-
like symptoms, such as rhinitis, cough and sore throat, but 
elderly subjects are more prone to lower respiratory 
symptoms such as wheezing and dyspnea [40,  42-44]. 
Overall, in the elderly, MPV infections are likely to be less 
severe than RSV infection and influenza [40]. The risk 
factors for severe illness, in addition to old age and 
institutionalization, include immunosuppression and chronic 
cardiopulmonary illness. MPV usually causes mid-winter 
epidemics. Asymptomatic MPV infections are rare. There 
seem to be two proposed genotypes, A and B, and several 
subgenotypes of MPV [45, 46], and thus it is unlikely that 
infection by either genotype of MPV confers cross-
protective immunity. The diagnosis of MPV infections is 
based on PCR, but immune fluorescence assays are also 
available. Several vaccine candidates are being investigated 
[47, 48]. 
SARS-ASSOCIATED CORONAVIRUS 
  The pandemic caused by SARS-CoV (SARS = severe 
acute respiratory syndrome) initiated in November 2002 in 
Guangdong province, China. It affected more than 8000 
patients and caused 774 (approximately 10%) deaths of all 
ages on 5 continents during an approximately 12 month 
period [20, 49, 50]. Infection by SARS-CoV was almost 
exclusively symptomatic resembling influenza with initial 
symptoms of fever, myalgia, malaise
 and chills or rigor [49]. 
Cough was common, but dyspnea was prominent only later 
in the course of the illness. Death was usually due to 
respiratory failure or a sepsis-related syndrome. Advanced 
age and co-morbidities increased markedly the risk of severe 
illness [50]. PCR tests have been rapidly developed and 
serology is also available [19, 20, 49]. No effective treatment 
is available, but interferons and ribavirin seem to inhibit 
virus replication [49]. Since the inflammation is part of the 
pathogenesis of this disease, corticosteroids may also be 
helpful if combined with antiviral medication [49]. Several 
new antivirals and vaccine candidates are being investigated. 
CORONAVIRUSES NL63 AND HKU1 
  In addition to coronaviruses 229E and OC43, the new 
coronaviruses NL63 and HKU1 were identified in samples 
of patients with respiratory symptoms in 2005-2006 [18, 21, 
22, 44, 51, 52]. Like other coronaviruses, NL63 and HKU1 
can be detected in a small percentage of individuals of all 
ages [53]. These viruses have primarily been associated with 
mild upper respiratory tract infections, but severe lower 
respiratory tract infections have also been reported [51, 52]. 
Diarrhea and abdominal pain may also occur, but symptoms 
and signs relate primarily to the respiratory tract [53-56]. 
Chronic underlying conditions and advanced age increase the 
susceptibility and disease severity of CoV infections, and 
mortality occurs [44, 53]. In a study of community-acquired 
pneumonia, most of the HKU1-positive patients were old 
(median age 72 years) and had significant underlying 
diseases, especially of the respiratory and cardiovascular 
systems [18]. One study reported an outbreak of acute 
respiratory infection in a personal-care home, where CoV 
NL63 was identified in 7 of 8 patients aged >50 years [57]. 
One elderly patient died 5 days after the onset of HCoV-
NL63 infection. CoV-NL63 and CoV-HKU1 are distributed 
throughout the globe and throughout the year, although they 
usually peak in the winter time [54] and cause irregular 
epidemics every 2–3 years [58]. Since these viruses are 
difficult to culture, diagnostic tests other than PCR are not 
available. There is neither specific antiviral therapy nor 
vaccine available for HCoV infections [59]. 
HUMAN BOCAVIRUS 
  The prevalence of HBoV DNA in respiratory specimens 
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for a primary HBoV infection is 6-48 months [62]. HBoV 
occurs world wide and throughout the year. HBoV has been 
associated with upper and with lower respiratory tract 
infections in children [62-66], but very little is known about 
HBoV infections among elderly people. HBoV has also been 
detected in the feces, in 1-9% of small children with or 
without gastrointestinal or respiratory symptoms [67-70] as 
well as in river and sewage water [71, 72], but whether it is a 
true enteric pathogen is not known. 
  Although HBoV infections are usually diagnosed with 
PCR, serological studies have shown that the mere presence 
of HBoV DNA in the respiratory tract is not proof of an 
acute primary HBoV infection [62, 73-75]. Studies on 
consecutive NPA samples have indeed shown that HBoV 
DNA can persist in the nasopharynx for several months [76, 
77]. Among adults, over 94% have antibodies to HBoV, 
indicating that they have encountered this virus during their 
lives [78, 79]. The prevalence figure is high and shows that 
HBoV infections are extremely common. Only a limited 
number of HBoV DNA-positive adults have been reported, 
mainly among immunosuppressed subjects, an observation 
that is in line with the high seroprevalence of HBoV [80-84]. 
This age pattern was, however, interestingly contradicted by 
a Canadian study that did not find differences in the 
prevalence of HBoV among different age groups [85]. In 
adults, HBoV-DNA positivity seems to be associated with 
symptoms, and therefore, HBoV cannot be considered 
simply an innocent bystander virus [81, 83, 86]. Since the 
discovery of HBoV, three other related bocaviruses (HBoV2, 
3 and 4) have been identified in human stool samples [69, 
87, 88]. 
HUMAN RHINOVIRUS, GROUPS C AND D 
  Human rhinovirus, the common cold virus, is the most 
common respiratory pathogen in all age groups [12]. In the 
two last decades of the last millennium it was thought that 
two major genetic groups, A and B, and 99 HRV serotypes 
exist. Novel PCR-based techniques, however, have identified 
additionally two groups, C and D, and possibly over 150 
different HRV strains [24, 89, 90]. Moreover, PCR has 
markedly increased the detection rates of HRV infections. 
HRV-infection is often associated with other pulmonary 
morbidity and is the most common virus (up to 60-70%) 
associated with exacerbations of asthma of all ages and with 
COPD in adults and the elderly [91-96]. In long-term care 
facilities HRV may cause serious morbidity and mortality, 
and goes often unrecognized. Louie et al. (2005) reported an 
epidemic of respiratory illness in a long-term care facility, 
which caused a mortality rate of 21% (12/56 affected 
residents died) [10]. Seven of 13 respiratory specimens were 
culture-positive for rhinovirus [10]. Hicks et al. (2006) 
reported two nursing home outbreaks of respiratory illness 
that caused the death of 7 residents out of 294 (2.4%). Of the 
29 collected samples, 10 (34%) were positive for rhinovirus 
[11]. There is an overall paucity of data on HRV-infections 
in the elderly. 
  Rhinovirus may in exceptional instances cause chronic 
lung infections which may have a duration of more than 12 
months. Such prolonged infections may occur in 
immunocompromized subjects with lung transplants or 
hypogammaglobulinemia [96, 97]. The recently identified 
group C HRV appears to be related to high morbidity. This 
virus has circulated at a rate similar to those of the HRV-A 
and -B groups [24, 98, 99] and is the cause for almost half of 
all HRV-associated hospitalizations in children [100, 101]. 
Different HRV strains circulate in the community throughout 
the year, but HRV epidemics typically peak in fall and 
spring. Diagnosis is based on PCR since these viruses are 
difficult to culture and serology is not feasible. 
KI AND WU POLYOMAVIRUSES 
  In addition to the previously known polyomaviruses, BK 
and JC, seven new human polyomaviruses have been 
identified in rapid sequence in 2007-2011. Two of them, 
detected in the respiratory tract samples, have been named 
by the institutes where they have been found: KI (Karolinska 
Institute) polyomavirus (KIPyV) and WU (Washington 
University) polyomavirus (WUPyV) [25, 26]. Two have 
been named by the diseases in association with which they 
were detected, MCPyV from a skin cancer called Merkel-cell 
carcinoma and TSPyV from a skin disease called 
trichodysplasia spinulosa [102, 103]. The remaining three 
polyomaviruses were also detected in skin samples, and 
named by numbers, PyV6, 7 and 9 [104-106]. The 
prevalence of the respiratory KI- and WU-polyomaviruses is 
2-7% in patients with respiratory symptoms [25, 26]. Most 
patients with KI- or WUPyV DNA in their upper airways, 
are young children with symptoms of rhinitis, cough, 
bronchiolitis and even pneumonia. Serologic studies show 
seroprevalences of 50 to 80% for KI- and WUPyVs in 
healthy children and adults [108-110]. 
  Data on the occurrence of these viruses in the elderly are 
lacking but are urgently needed, since PyVs are potentially 
oncogenic and can persist in human tissues [103, 111]. KI- 
and WUPyV become reactivated at similar frequencies as the 
BK and JC viruses during immunosuppression [111, 112]. 
Diagnostics is based on PCR and serology [107, 109]. 
TORQUE TENO VIRUS 
  Torque teno virus DNA has been recovered from many 
tissues and secretions but whether this observation is 
causally related to clinical symptoms or not has not been 
demonstrated [14, 113-115]. TTV is possibly able to 
replicate in airway tissues [116, 117] and many other tissues 
e.g. liver and bone marrow [118]. The airways might be the 
primary route of transmission. TTV is very often detected in 
blood; the prevalence of TTV DNA in the blood of healthy 
individuals is approximately 70-90% [119]. A single TTV 
infection may persist for years and cause chronic viremia 
[120-122]. Simultaneous infections by different TTV 
variants may also occur. TTV might also aggravate the 
symptoms caused by other respiratory viruses, or then TTV 
may be an indicator of the disease process as implied by the 
findings that TTV concentrations in nasal secretions or 
plasma have a positive correlation with markers of 
eosinophilic inflammation and a negative correlation with 
pulmonary function in asthma [15]. Also, the severity of 
bronchiectasis and of idiopathic pulmonary fibrosis correlate 
with high TTV concentrations [115]. The association 
between TTV and disease, could be based on a direct viral 
effect or be mediated by inflammatory processes that 
predispose to virus replication. Indeed, TTV replication 
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reconstitution after suppression [123]. Although multiple 
TTV variants cause problems in detection, the diagnosis of 
TTV infections is based on PCR; serology will apparently 
not be developed in the near future [124]. 
DIAGNOSIS 
  Making a clinical diagnosis of a respiratory viral illness 
for elderly patients poses a challenge. The clinical picture is 
much more blurred in comparison to the typical upper 
respiratory infection, seen in children and young adults [35, 
125-127]. Viral infections are usually due to reinfection, and 
elderly adults usually have some degree of immunity [128]. 
Because of pre-existing systemic and mucosal antibodies, 
elderly adults have probably lower amounts of respiratory 
secretions and lower viral loads as compared to children. 
Among elderly patients respiratory viral illness may 
accompany symptoms of lower respiratory tract 
involvement, pulmonary and cardiac failure, and nonspecific 
or atypical symptoms such as confusion, anorexia, dizziness, 
falls and lack of fever [125-128]. Finally, some elderly may 
also be unable to articulate their symptoms clearly, 
something they have in common with infants [128]. 
  A further challenge to the diagnostics of viral illness is 
optimal sampling. Nasopharyngeal swabs, aspirates or 
washes are traditionally used in children but they are not 
well tolerated in older adults or older people. The best way 
and time to take samples for viral diagnostics are not known 
for the elderly. Although nasopharyngeal swab sampling is a 
sensitive and sufficient method for children [129, 130], this 
simplest sampling method may be difficult to apply to adults 
[131]. To obtain a sufficient sample and viral load, optimal 
sampling probably requires both nasopharyngeal and 
oropharyngeal sampling. Taking swab samples is probably 
the quickest way and causes the least discomfort while 
nasopharyngeal washing may collect more viruses [128, 
131]. 
  Of the conventional diagnostic methods available for 
these new respiratory viruses, serology is available for the 
influenza virus, MPV, HBoV and PyVs [62, 73, 109, 132, 
133]. However, serology is not often practical in the acute 
phase. Of the other conventional methods, a rapid antigen 
detection test is available for the influenza virus. Some 
reports suggest that a rapid antigen detection test is relatively 
sensitive for detection of the influenza virus in elderly 
patients; during outbreaks up to 77% are detected by rapid 
antigen testing of culture positive samples [133, 134]. Other 
studies have reported much lower sensitivities (38-43% 
compared with PCR) [135, 136]. The sensitivity may be only 
8-22% in patients ! 80 years of age [137]. Despite a poor 
sensitivity, the rapid antigen detection test is highly specific 
for detecting influenza viruses in the elderly 
  All new respiratory viruses can be diagnosed by sensitive 
PCR methods [44]. When diagnosing acute HBoV or SARS-
CoV infection, PCR needs to be complemented with 
serology. Currently, up to 85-95% of all viruses in 
respiratory samples of children with respiratory symptoms 
may be detected [61, 138-142]. PCR is the best choice also 
for the elderly since it is the most sensitive method for 
detection of viruses in this age group as well [136, 143-147], 
although the detection rates, probably due to the difficulties 
in sampling, decline with age. The detection rates among 
elderly patients have remained below 40% even in 
exacerbations of chronic pulmonary disease [91, 92, 95, 148] 
and viral pneumonia [149]. The rates in the intermediate age 
groups, i.e., adults with exacerbations of COPD or asthma 
have been up to 64% [150-152]. The actual prevalences of 
the new viruses among the elderly population are not known 
[5, 7, 10, 11, 148, 153]. 
  The interpretation of positive PCR results is complicated 
by multiple co-existing viruses especially in symptomatic 
children (up to 43%) and by high virus detection rates in 
asymptomatic subjects (up to 40-68% in young children) 
[139, 154-157]. In a review of the literature that goes back to 
1965 and stretches to 2008, the prevalence of viruses in 
15000 samples from asymptomatic subjects was higher by 
PCR than by conventional methods [158]. This casts some 
doubt on the clinical significance of PCR-positive viral 
findings overall. Several studies have, on the other hand, 
demonstrated that positive PCR results are clinically relevant 
at least as far as HRV is concerned. Identification of HRV 
correlates with respiratory symptoms, dual HRV infections 
are rare and overall, the prevalence of recurrent or persistent 
respiratory viral infections (excluding TTV and HBoV) is 
low (3-4%) [96, 158-160]. Positive findings with PCR 
correlate with systemic or local immune responses in 
children and in adults [161-163].  These findings, which 
mainly apply to HRV and not to HBoV, suggest that HRV-
PCR positivity probably reflects a true, current respiratory 
infection with or without symptoms, rather than residual 
nucleic acids from some other distant infection. Of course, 
any findings in upper airway samples do not necessarily 
reflect the situation in lower airways [164]. Multiple PCR 
analyses of single samples (multiplex PCR) may sound 
attractive, but the sensitivity for identification of individual 
viruses may be lost compared to single virus PCR [165]. Of 
note, most of these data are from studies on children and 
adults, and data on new respiratory viruses in the elderly are 
scarce. 
IMMUNOSENESCENCE 
  The term immunosenescence describes the deleterious 
age-associated changes in the immune system that render 
elderly individuals susceptible to infectious disease and 
increases morbidity and mortality [3, 166]. With age, all 
components of immunity are affected, but the T cells are the 
most susceptible [167]. Although the adaptive function of 
immunity appears to be more seriously affected than the 
innate immune system, the increased susceptibility to lower 
respiratory tract viral infections relates particularly to 
defective innate immunity [163, 168]. The weakening 
immune responses could be linked to the over-all long-term 
poor outcome in the elderly [166]. Immunosenescence is a 
multifactorial process and is associated with thymic 
involution, chronic antigenic stimulation (predominantly 
attributable to persistent infections), signal transduction 
changes in immune cells, and protein-energy malnutrition 
[169]. There is a paucity of accurate data on the link between 
the causes of death of elderly and the age-associated changes 
in the immune system. 
TREATMENT 
  With the exception of the influenza viruses, there are no 
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viruses. In this sense, there is no clinical need for a viral 
diagnosis. Viral detection may still have practical importance 
with regard to isolating practices of infected patients in 
hospitals or in long-term care settings to prevent 
transmission of disease [128] and for proper supportive 
treatment, including avoidance of unnecessary antibiotic 
treatments [146]. 
  An increased susceptibility to viral infections could be a 
marker of a pulmonary inflammatory processes, and indicate 
a need for intensified treatment of chronic pulmonary illness. 
For example, TTV and AdV infections are associated with a 
chronic inflammatory state of the lungs [15, 170-173]. In 
children, there is a link between susceptibility to HRV-
induced wheezing and the development of asthma [174-178], 
and in adults, HRV is the most important trigger of 
exacerbations of COPD [91, 95]. 
  Current knowledge on bacterial-viral coinfections in the 
elderly is very limited. In community-acquired pneumonia of 
adults, there is evidence of mixed viral-bacterial infection in 
up to 15% of cases and in children up to 45 % of cases [179]. 
The most frequent combinations have been Streptococcus 
pneumoniae with influenza A virus or HRV. Bacterial and 
viral infections may act deleteriously through synergistic 
mechanisms. There may be destruction of the respiratory 
epithelium by the viral infection, which may increase 
bacterial adhesion; virus-induced immunosuppression may 
cause bacterial superinfections; and the inflammatory 
response to viral infection may up-regulate the expression of 
molecules that are suitable for bacteria as receptors [180]. 
  Vaccines are being developed against these new viruses. 
The most promising preclinical results have been reported 
for vaccine candidates for MPV and SARS-CoV, but their 
efficacy have not been studied in humans [181, 182]. 
CONCLUSIONS 
  The new respiratory viruses or viral strains include 
influenza A virus H5N1 and H1N1, MPV, SARS-, NL63- 
and HKU1-CoV, HBoV, HRV-C and –D and the possible 
respiratory pathogens, KI- and, WU-PyV and TTV [13, 14, 
17-28]. All these new viruses are distributed throughout the 
globe and affect people of all ages, but data on these viruses 
and the elderly are scarce. These new viral infections can be 
diagnosed by sensitive PCR methods. The viruses may be 
detectable in the airways for varying periods of time also 
after the acute phase and this leads to a diagnosis of several 
concomitant viruses. The classical predisposing factors to 
viral infections include advanced age, chronic illnesses and 
poor immune responses. The elderly often have partial 
immunity and chronic illnesses; these circumstances modify 
their responses to viruses and thus respiratory viral infections 
may manifest themselves as atypical symptoms or as 
exacerbation of chronic illnesses. Serious outbreaks have 
been reported in long-term care facilities. Vaccination is the 
most effective way to prevent serious disease, but it is only 
available for the influenza virus. Virus-specific treatment is 
also available only for the influenza virus. Early 
identification of a viral pathogen through improved viral 
diagnostics is crucial for successful treatment of viral 
illnesses. Preventive measures are also important, such as 
vaccinations, hand-washing and isolation of the affected 
individuals in hospitals and long-term care facilities. The 
ultimate clinical significance of the new respiratory viruses 
is still poorly unknown in the elderly population but 
probably these infections are greatly underestimated. 
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